162 related articles for article (PubMed ID: 29463526)
1. Elevated Plasma Moxifloxacin Concentrations and
Weiner M; Gelfond J; Johnson-Pais TL; Engle M; Peloquin CA; Johnson JL; Sizemore EE; Mac Kenzie WR
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463526
[TBL] [Abstract][Full Text] [Related]
2. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.
Weiner M; Peloquin C; Burman W; Luo CC; Engle M; Prihoda TJ; Mac Kenzie WR; Bliven-Sizemore E; Johnson JL; Vernon A
Antimicrob Agents Chemother; 2010 Oct; 54(10):4192-200. PubMed ID: 20660695
[TBL] [Abstract][Full Text] [Related]
3. Effect of Genetic Variation of
Dompreh A; Tang X; Zhou J; Yang H; Topletz A; Adu Ahwireng E; Antwi S; Enimil A; Langaee T; Peloquin CA; Court MH; Kwara A
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263072
[TBL] [Abstract][Full Text] [Related]
4. Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis.
Weiner M; Gelfond J; Johnson-Pais TL; Engle M; Johnson JL; Whitworth WC; Bliven-Sizemore E; Nsubuga P; Dorman SE; Savic R;
J Antimicrob Chemother; 2021 Feb; 76(3):582-586. PubMed ID: 33374006
[TBL] [Abstract][Full Text] [Related]
5. Variability in plasma rifampicin concentrations and role of
Sileshi T; Makonnen E; Telele NF; Barclay V; Zumla A; Aklillu E
Infect Dis (Lond); 2024 Apr; 56(4):308-319. PubMed ID: 38315168
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9*3(1075A > C), ABCB1 and SLCO1B1 genetic polymorphisms and gender are determinants of inter-subject variability in pitavastatin pharmacokinetics.
Zhou Q; Chen QX; Ruan ZR; Yuan H; Xu HM; Zeng S
Pharmazie; 2013 Mar; 68(3):187-94. PubMed ID: 23556337
[TBL] [Abstract][Full Text] [Related]
7. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).
Niemi M; Schaeffeler E; Lang T; Fromm MF; Neuvonen M; Kyrklund C; Backman JT; Kerb R; Schwab M; Neuvonen PJ; Eichelbaum M; Kivistö KT
Pharmacogenetics; 2004 Jul; 14(7):429-40. PubMed ID: 15226675
[TBL] [Abstract][Full Text] [Related]
8. Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.
Sloan DJ; McCallum AD; Schipani A; Egan D; Mwandumba HC; Ward SA; Waterhouse D; Banda G; Allain TJ; Owen A; Khoo SH; Davies GR
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461315
[TBL] [Abstract][Full Text] [Related]
9. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.
Thee S; Garcia-Prats AJ; Draper HR; McIlleron HM; Wiesner L; Castel S; Schaaf HS; Hesseling AC
Clin Infect Dis; 2015 Feb; 60(4):549-56. PubMed ID: 25362206
[TBL] [Abstract][Full Text] [Related]
11. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
[TBL] [Abstract][Full Text] [Related]
12. A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
Conde MB; Mello FC; Duarte RS; Cavalcante SC; Rolla V; Dalcolmo M; Loredo C; Durovni B; Armstrong DT; Efron A; Barnes GL; Marzinke MA; Savic RM; Dooley KE; Cohn S; Moulton LH; Chaisson RE; Dorman SE
PLoS One; 2016; 11(5):e0154778. PubMed ID: 27159505
[TBL] [Abstract][Full Text] [Related]
13. Effect of SLCO1B1 Polymorphisms on Rifabutin Pharmacokinetics in African HIV-Infected Patients with Tuberculosis.
Hennig S; Naiker S; Reddy T; Egan D; Kellerman T; Wiesner L; Owen A; McIlleron H; Pym A
Antimicrob Agents Chemother; 2016 Jan; 60(1):617-20. PubMed ID: 26482301
[TBL] [Abstract][Full Text] [Related]
14. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
Peloquin CA; Hadad DJ; Molino LP; Palaci M; Boom WH; Dietze R; Johnson JL
Antimicrob Agents Chemother; 2008 Mar; 52(3):852-7. PubMed ID: 18070980
[TBL] [Abstract][Full Text] [Related]
16. Relationship among genetic polymorphism of SLCO1B1, rifampicin exposure and clinical outcomes in patients with active pulmonary tuberculosis.
Kim ES; Kwon BS; Park JS; Chung JY; Seo SH; Park KU; Song J; Yoon S; Lee JH
Br J Clin Pharmacol; 2021 Sep; 87(9):3492-3500. PubMed ID: 33538008
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.
Kwara A; Cao L; Yang H; Poethke P; Kurpewski J; Tashima KT; Mahjoub BD; Court MH; Peloquin CA
Pharmacotherapy; 2014 Mar; 34(3):265-71. PubMed ID: 24420746
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.
Jing W; Zong Z; Tang B; Wang J; Zhang T; Wen S; Xue Y; Chu N; Zhao W; Huang H
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907179
[TBL] [Abstract][Full Text] [Related]
19. Repaglinide-irbesartan drug interaction: effects of SLCO1B1 polymorphism on repaglinide pharmacokinetics and pharmacodynamics in Chinese population.
Pei Q; Liu JY; Yin JY; Yang GP; Liu SK; Zheng Y; Xie P; Guo CX; Luo M; Zhou HH; Li X; Liu ZQ
Eur J Clin Pharmacol; 2018 Aug; 74(8):1021-1028. PubMed ID: 29748863
[TBL] [Abstract][Full Text] [Related]
20. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study.
Pletz MW; De Roux A; Roth A; Neumann KH; Mauch H; Lode H
Antimicrob Agents Chemother; 2004 Mar; 48(3):780-2. PubMed ID: 14982764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
